US Graphic Warning Implementation Delayed to 2023

Aug.15.2022
US Graphic Warning Implementation Delayed to 2023
Implementation of US graphic health warnings delayed until October 6, 2023, due to legal challenges and Covid-19.

According to the Winston-Salem Journal, the implementation date for the U.S. graphic health warnings has been postponed by three months to October 6, 2023.


On August 10th, a judge from a Texas regional court approved the latest delay in the release date for the graphic health warnings. This is at least the ninth time a judge has ordered a delay.


The US Food and Drug Administration (FDA) issued a final rule in March 2020 requiring new graphic warnings on cigarette packages. The rule mandates the use of labels featuring lesser-known smoking health risks, such as diabetes, and the warnings must cover the top 50% of both the front and back panels of packages and at least 20% of top advertising space.


In April and May of 2020, cigarette manufacturers and retailers sued the FDA, arguing that the graphic warning requirements were equivalent to government anti-smoking propaganda because the government has never forced legal product manufacturers to use their own ads to spread messages urging adults not to use their products.


In a recent challenge, tobacco companies argued that the deadline delay due to the impact of the COVID-19 pandemic has become too burdensome. They also pointed out that if graphic health warnings are required to be rejected in court again, they face the risk of losing new packaging investments. In March 2021, a regional court in Texas approved the motion by the plaintiffs to postpone the effective date of the final rule until April 14, 2022. This resulted in an additional delay.


Statement:


This article is based on compiled information from a third party and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry exchange and research purposes.


Due to limitations in the compiler's abilities, this article's translation may not be an exact representation of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign issues and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
VAPORESSO has listed the LUXE X3, a new addition to its LUXE X series, on its official website. The device features a 2,600mAh built-in battery, adjustable 5–45W output and a 0.8-inch digital display, and comes with a 5ml pod (2ml for the TPD version). The LUXE X3 has also appeared on some UK and US online retailers for pre-order, with prices below the company’s stated MSRP of $37.9.
Jan.19 by 2FIRSTS.ai
Six Years of Data Show FDA Clearing PMTA Backlog
Six Years of Data Show FDA Clearing PMTA Backlog
FDA data from FY2020 to FY2025 show how the PMTA system for e-cigarette products evolved after an early surge of submissions created prolonged front-end delays. Millions of applications accumulated at the Acceptance stage before entering substantive review. Since 2023, the number of applications pending acceptance has declined sharply, and industry participants report shorter initial decision timelines in late 2025.
Feb.06
Echo Guo: The Accumulating Risks Behind the Surge in Chinese Vape Exports to the U.S.
Echo Guo: The Accumulating Risks Behind the Surge in Chinese Vape Exports to the U.S.
Chinese vape exports to the U.S. jumped from about 2.2 million kg in June to 14.8 million kg in October 2025, despite tougher enforcement, the Washington Examiner reported. 2Firsts finds the surge reflects delayed bulk shipments, not demand recovery. With U.S. inventory exceeding 160 million devices and distributors paying ~10% upfront, cash-flow stress has shifted to Chinese manufacturers, and discounted stock is spilling into other markets.
Dec.14 by Echo Duo
10,800 Vape Cartridges Worth USD 175,000 Confiscated in Maldives
10,800 Vape Cartridges Worth USD 175,000 Confiscated in Maldives
The Maldives Customs Service has confiscated the largest single shipment of vapes since the national import ban took effect in November 2024. Officials searched a sea freight shipment on December 4 and seized 10,800 vape cartridges valued at approximately MVR 2.7 million (USD 175,000).
Dec.11 by 2FIRSTS.ai
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands said in a statement on its website that John Rishton will join the board in July 2026 and assume the role of chair in December, succeeding current chair Thérèse Esperdy, who will retire at that time.
Jan.21 by 2FIRSTS.ai
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
An exclusive 2Firsts investigation found an unpublished FDA update on e-cigarette marketing authorizations that mirrors market speculation, suggesting Glas’s application may have cleared internal review, though no official confirmation has been issued.
Regulations
Dec.21